Initial Phase 1 Dose Escalation Data for Emi-Le (emiltatug ledadotin; XMT-1660)
Learnings from Translational and Clinical Development of Dolaflexin and Dolasynthen ADCs
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer
April, 2022
XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer
April, 2021